Back to Journals » Cancer Management and Research » Volume 12

Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer

Authors Wu Y, Zhang Y, Pi H, Sheng Y

Received 20 February 2020

Accepted for publication 16 April 2020

Published 15 May 2020 Volume 2020:12 Pages 3477—3487

DOI https://doi.org/10.2147/CMAR.S250632

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Chien-Feng Li


Yanmei Wu,1 Yu Zhang,2 Hao Pi,1 Yuan Sheng1

1Department of Breast and Thyroid Surgery, Changhai Hospital, Navy Medical University, Shanghai 200433, People’s Republic of China; 2Medical Affairs, Pfizer Biopharmaceutical Group, Shanghai 200041, People’s Republic of China

Correspondence: Yuan Sheng
Department of Breast and Thyroid Surgery, Changhai Hospital, Navy Medical University, Shanghai 200433, People’s Republic of China
Email sheng528yuan@126.com

Abstract: The clinical use of selective cyclin-dependent kinase (CDK) 4/6 inhibitors has significantly improved the prognosis of patients with hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (ABC/mBC), which almost achieved the double progression-free survival (PFS) in combination with endocrine therapy (ET) compared with ET alone. To date, there are 3 CDK4/6 inhibitors (palbociclib, ribocilcib and abemaciclib) approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to treat patients with HR+/HER2-ABC/mBC in the first and later lines. The aim of this review is to summarize the current clinical use and ongoing clinical trials of CDK4/6 inhibitors, the published overall survival data, and the potential biomarkers and resistance to CDK4/6 inhibitors.

Keywords: CDK4/6 inhibitor, breast cancer, mechanism, clinical efficacy, resistance

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]